Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin.
- DOI
- 10.1038/s41598-020-80415-w
- Published
- 2021 Jan 8
- Container
- Scientific reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41598-020-80415-w,
title = {Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin.},
author = {Liu W and Chen W and Zhang X and Zhao P and Fan Z and Bi L and Wu D and Li S and Yang M and Fu T and Song D and Han B and Zhao G and Du Y and Shi A},
year = {2021},
journal = {Scientific reports},
doi = {10.1038/s41598-020-80415-w},
url = {https://doi.org/10.1038/s41598-020-80415-w}
}RIS
TY - JOUR TI - Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin. AU - Liu W AU - Chen W AU - Zhang X AU - Zhao P AU - Fan Z AU - Bi L AU - Wu D AU - Li S AU - Yang M AU - Fu T AU - Song D AU - Han B AU - Zhao G AU - Du Y AU - Shi A PY - 2021 JO - Scientific reports DO - 10.1038/s41598-020-80415-w UR - https://doi.org/10.1038/s41598-020-80415-w ER -
APA
W, L., W, C., X, Z., P, Z., Z, F., L, B., D, W., S, L., M, Y., T, F., D, S., B, H., G, Z., Y, D., & A, S. (2021). Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin.. Scientific reports. https://doi.org/10.1038/s41598-020-80415-w
Source records
- pubmed · retrieved 2026-11-10T13:20:48.434Z